HighlightsWHO vaccine hesitancy definition understood; >90% countries report hesitancy.Long list of reasons, varied by country income level; WHO region, changed overtime.Most cited: risk-benefit (scientific evidence) equaled <25% of reasons cited.Reasons cited based on assessments in only 1/3 of countries; need to increase this.

The findings demonstrate that a formal process of tracking cancer clinical trial screens using an EMR can document baseline rates of institution-specific accrual patterns and identify targeted strategies for increasing cancer clinical trial enrollment among a vulnerable patient population. Offering nontreatment trials may be an important and strategic method of engaging this vulnerable population in clinical research.